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ABSTRACT
Preterm preeclampsia (PE), occurring at < 37 weeks’ gestation, can be predicted from as early as 11-13 weeks and prevented 
with the use of aspirin. In contrast, term PE, which is more common than preterm-PE and it can be associated with important 
maternal morbidity and mortality, cannot be effectively predicted at 11-13 weeks and cannot be prevented by the prophy-
lactic use of aspirin. This paper briefly reviews the pathogenesis of term PE and discusses strategies available for its prediction. 
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INTRODUCTION
Preeclampsia (PE) is one of the leading causes of maternal 
and fetal morbidity and mortality worldwide [1] and compli-
cates about 3% of all pregnancies [2]. The pathogenesis of PE 
is not yet completely understood with some considering it 
a single disorder with a wide range of clinical manifestations 
[2–4] while others, as two distinct conditions [5]. 
Recent evidence suggests that preterm-PE, occurring 
at < 37 weeks’ gestation, is to a great extent predictable 
and preventable. Effective screening for preterm-PE can be 
provided by a combination of maternal factors, mean arterial 
pressure (MAP), Doppler assessment of the uterine artery 
pulsatility index (UTPI) and placental growth factor (PLGF) 
at 11–13 weeks’ gestation with detection rate (DR) of 75% 
at false positive rate (FPR) of 10% [2–4]. Prophylactic use of 
aspirin (aspirin 150 mg/day from 11–14 weeks’ gestation to 
36 weeks) on the high-risk group by first-trimester combined 
screening reduces the risk of preterm-PE by > 60% [6, 7]. 
In contrast, the performance of first-trimester combined 
screening for term-PE is poor, with DR of 45% at FPR of 10% 
[2] and prophylactic use of aspirin is not beneficial [6, 7].
In this article we discuss available models of prediction 
for term PE.
IMPORTANCE OF TERM PREECLAMPSIA
One-third of all the cases of PE occur preterm and are 
associated with high levels of neonatal morbidity and mor-
tality and severe maternal complications. Two-thirds of cases 
are term-PE (Fig. 1) [2].
Although term PE is traditionally considered less dan-
gerous, mainly because delivery is safe at this stage for 
the fetus, it is not deprived of maternal complications and, 
because term PE is much more common than preterm PE, 
most of the maternal complications that will be diagnosed 
in association with PE will be actually confined to this gro-
up. In the Confidential Enquiry into Maternal Deaths form 
the United Kingdom, 50% of all cases of maternal deaths 
attributable to PE were due to term PE [8]. The same point is 
made by a study from the United States where the authors 
reported 985 cases of severe maternal morbidity in associa-
tion with PE developing after 34 weeks and only 289 with 
Figure 1. Incidence of preterm and term preeclampsia
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early-onset PE in a studied population of 670,120 singleton 
pregnancies [9]. Therefore, term-PE is not an innocuous con-
dition; it should not be overlooked and prediction models 
and prevention strategies should be put forward. 
PATHOGENESIS OF TERM PREECLAMPSIA
The development of PE requires both placental and 
maternal contributions (Fig. 2).
Preterm-PE in likely to reflect impaired placentation with 
failure of physiological transformation of the spiral arteries 
between 8 and 18 weeks of pregnancy. It is associated with 
fetal growth restriction, prominent placental pathology and 
abnormal Doppler velocimetry in the uterine arteries. By 
contrast, in term-PE the placental contribution seems less 
important, UTPI is often normal and there is usually normal 
fetal growth [10–13]. Rather, it seems that for term-PE, a ma-
ternal threshold for “tolerance” to the burden of pregnancy 
is achieved and that maternal characteristics such as being 
obese, having metabolic syndrome, comorbid conditions 
or insulin resistance are more likely to play a role [14–17].
Preterm- and term-PE, also appear to develop from dif-
ferent hemodynamic states. Term-PE appears to be more 
frequent in patients with high body mass index, increased 
cardiac output and relatively unchanged total vascular re-
sistance; whereas patients with preterm-PE have lower BMI 
and relatively increased vascular resistance [18].
The angiogenic marker profile also seems to be different 
in preterm- and term-PE. Both are associated with altered 
serum levels of the anti-angiogenic marker soluble fms-like 
tyrosine kinase-1 (SFLT-1) and the pro-angiogenic PLGF, 
however the alterations are more pronounced in preterm- 
than term-PE [19]. Interestingly, for suspected PE before 
35 weeks, a decrease in the maternal serum levels of PLGF 
has been shown to rule in women requiring delivery within 
14 days. However, this test’s performance falls off in women 
presenting after 35 weeks [20, 21].
PREDICTION OF PREECLAMPSIA 
DEVELOPING AT TERM
The traditional approach to screening for PE is to use 
a risk-scoring system based on maternal demographic 
characteristics and medical history (maternal factors) [22]. 
However, the performance of such approach, which essen-
tially treats each risk factor as a separate screening test with 
additive detection rate and screen positive rate, is poor [23]. 
Another approach in screening for PE has been pro-
posed by the Fetal Medicine Foundation (FMF) [2, 3] This 
approach, which is based on a survival time model, assu-
mes that if the pregnancy was to continue indefinitely, all 
women would develop PE and whether they do so or not 
before a specified gestational age depends on a competi-
tion between delivery before or after development of PE. 
The effect of variables from maternal characteristics and 
history (maternal factors) and biomarkers is to modify the 
mean of the distribution of gestational age at delivery with 
PE, so that in pregnancies at low risk for PE the gestational 
age distribution is shifted to the right with the implication 
that in most pregnancies delivery will occur before the de-
velopment of PE. In high-risk pregnancies the distribution 
is shifted to the left. An algorithm combining maternal risk 
factors such as age, weight, racial origin, obstetric history, 
family history of PE, method of conception, comorbidities 
as chronic hypertension, diabetes mellitus, systemic lupus 
erythematosus, antiphospholipid syndrome and MAP, UTPI, 
serum PLGF and SFLT-1 is used at different stages in pre-
gnancy to detect those at high risk for PE and offer various 
interventions. 
The performance of screening for term-PE by a com-
bination of maternal factors with biomarkers (MAP, UTPI, 
PLGF and SFLT) at 12, 22 or 32 weeks’ gestation is relatively 
poor with respective DR of about 45%, 45% and 65%, at 
FPR of 10% [2, 24, 25]. The best performance of screening 
for term-PE is achieved when screening is performed at 
35–37 weeks, with DR of about 85% at FPR of 10% (Fig. 3) 
[26]. The values of MAP, UTPI and SFLT-1 are increased and 
serum PLGF is decreased compared to unaffected pregnan-
cies. For all biomarkers the deviation from normal is inversely 
related to the gestational age at which delivery becomes 
necessary for maternal or fetal indications. We have there-
fore proposed that all women, irrespective of whether they 
had prior screening or not, should have assessment of risk 
at 35–37 weeks [27]. 
On the basis of the results from screening at 35–37 we-
eks the pregnancies can be stratified into three different 
management pathways (Fig. 4) [27]. 
Figure 2. Preeclampsia requires both placental and maternal 
contributions for its development. An important degree of placental 
impairment would lead to manifestations of PE even in the absence 
of significant maternal contribution, while, in a mother with severe 
metabolic and vascular derangements, as with chronic hypertension, 
PE could develop with minimal placental contribution
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First, a low-risk group (risk for PE of < 1 in 200) consti-
tutes about 40% of the total and has a > 99.9% chance of 
not developing PE; this group can be reassured that deve-
lopment of PE is very unlikely and in the absence of any 
abnormal ultrasound findings or other obstetric indications 
the pregnancies can be managed expectantly awaiting for 
spontaneous onset of labor.
Second, a high-risk group (risk for PE at < 40 weeks 
of ≥ 1 in 100) constitutes about 20% of the total and conta-
ins > 90% of those that develop PE at < 40 weeks. This group 
can be monitored by measurement of blood pressure and 
urinalysis at least on a weekly basis and the women can be 
advised to report any of the symptoms associated with 
severe PE, such as visual disturbance and epigastric pain. 
An alternative strategy that is currently being investigated 
by a major multicenter randomized study is to treat these 
pregnancies by pravastatin with the aim of reducing the 
risk of developing PE. 
Third, an intermediate-risk group  (risk between the 
high- and low-risk groups above). This group, together with 
the high-risk group that remains undelivered by 40 weeks’ 
gestation, constitutes about 60% of the total and contains 
almost all cases of PE at > 40 weeks. These pregnancies require 
reassessment at 40 weeks to decide the best time for delivery.
The cut-offs in risks to define the proportion of the popu-
lation stratified into each of the three management groups 
and the protocols for such management will inevitably vary 
according to local preferences and health economic conside-
rations. Future studies will examine whether the implemen-
tation of such protocols could improve perinatal outcome.
CONCLUSIONS
Term-PE is the most common form of PE and it can be as-
sociated with important maternal morbidity and mortality. 
The best performance of screening for term-PE is achieved 
by a combination of maternal factors, MAP, UTPI, PLGF and 
SFLT at 35–37 weeks’ gestation. Using this approach, a DR 
of 85% can be achieved for FPR of 10%. On the basis of the 
results from screening the pregnancies can be stratified into 
three different management pathways.
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Figure 3. Detection rates in screening for term PE at 11–13, 20–24, 30–
–34 and 35–37 weeks using the FMF algorithm that combines maternal 
factors and characteristics with mean arterial pressure (MAP), doppler 
assessment of the uterine artery pulsatility index (UTPI), placental 
growth factor (PLGF) and soluble Fms-like tyrosine kinese-1 (SFLT-1)
FPR — false positive rate  
Figure 4. Stratification of pregnancies into high-, intermediate- 
and low-risk management groups based on the estimated risk for 
preeclampsia at 35–37 weeks’ gestation. The high-risk group would 
require intensive monitoring from the time of the initial assessment 
and up to 40 weeks’ gestation, the intermediate-risk group would 
require reassessment at 40 weeks’ gestation and the low-risk group 
would be managed expectantly
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